These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2973485)

  • 21. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group.
    Topol EJ; Ellis SG; Califf RM; George BS; Stump DC; Bates ER; Nabel EG; Walton JA; Candela RJ; Lee KL
    J Am Coll Cardiol; 1989 Oct; 14(4):877-84. PubMed ID: 2477426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergency coronary artery bypass surgery preserves global and regional left ventricular function after intravenous tissue plasminogen activator therapy for acute myocardial infarction.
    Kereiakes DJ; Topol EJ; George BS; Abbottsmith CW; Stack RS; Candela RJ; O'Neill WW; Martin LH; Califf RM
    J Am Coll Cardiol; 1988 May; 11(5):899-907. PubMed ID: 2965716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variables predictive of good functional outcome following thrombolytic therapy in the Thrombolysis in Myocardial Infarction phase II (TIMI II) pilot study.
    Rogers WJ; Bourge RC; Papapietro SE; Wackers FJ; Zaret BL; Forman S; Dodge HT; Robertson TL; Passamani ER; Braunwald E
    Am J Cardiol; 1989 Mar; 63(9):503-12. PubMed ID: 2521976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
    Lincoff AM; Topol EJ; Califf RM; Sigmon KN; Lee KL; Ohman EM; Rosenschein U; Ellis SG
    Am J Cardiol; 1995 May; 75(14):871-6. PubMed ID: 7732992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial.
    Rogers WJ; Baim DS; Gore JM; Brown BG; Roberts R; Williams DO; Chesebro JH; Babb JD; Sheehan FH; Wackers FJ
    Circulation; 1990 May; 81(5):1457-76. PubMed ID: 2110033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reperfusion therapy in inferior myocardial infarction.
    Bates ER
    J Am Coll Cardiol; 1988 Dec; 12(6 Suppl A):44A-51A. PubMed ID: 3142944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
    Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
    J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
    Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
    J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary intracoronary stenting in comparison with intravenous rt-PA thrombolysis plus rescue intracoronary intervention in patients with acute myocardial infarction.
    Zhang D; Cai X; Zhang R; Zhang J; Shen W
    Chin Med J (Engl); 2002 Feb; 115(2):163-5. PubMed ID: 11940322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination thrombolytic therapy: a comparison of simultaneous and sequential regimens of tissue plasminogen activator and urokinase.
    Morris JA; Muller DW; Topol EJ
    Am Heart J; 1991 Aug; 122(2):375-80. PubMed ID: 1907086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. The European Cooperative Study Group.
    Lenderink T; Simoons ML; Van Es GA; Van de Werf F; Verstraete M; Arnold AE
    Circulation; 1995 Sep; 92(5):1110-6. PubMed ID: 7648654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    Klin Wochenschr; 1988; 66 Suppl 12():102-8. PubMed ID: 3126339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An overview of the thrombolysis and angioplasty in acute myocardial infarction (TAMI) trials.
    Topol EJ
    Arch Mal Coeur Vaiss; 1988 May; 81 Spec No():45-9. PubMed ID: 2973302
    [No Abstract]   [Full Text] [Related]  

  • 36. The thrombolysis and angioplasty in myocardial infarction (TAMI) trial: review and nursing implications.
    Pitts P; Fenwick B; Fromberg B
    Prog Cardiovasc Nurs; 1990; 5(2):65-72. PubMed ID: 2116622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group.
    Topol EJ; Califf RM; Vandormael M; Grines CL; George BS; Sanz ML; Wall T; O'Brien M; Schwaiger M; Aguirre FV
    Circulation; 1992 Jun; 85(6):2090-9. PubMed ID: 1591828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction.
    Topol EJ; Califf RM; George BS; Kereiakes DJ; Rothbaum D; Candela RJ; Abbotsmith CW; Pinkerton CA; Stump DC; Collen D
    Circulation; 1988 May; 77(5):1100-7. PubMed ID: 2966017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion.
    Gold HK; Leinbach RC; Garabedian HD; Yasuda T; Johns JA; Grossbard EB; Palacios I; Collen D
    Circulation; 1986 Feb; 73(2):347-52. PubMed ID: 3080262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.